CD274 and neoplasm: Only 9 of the approvals were linked to a specific PD-L1 threshold and companion diagnostic assay, with variable thresholds both within and across tumor types using several different assays, suggesting that PD-L1 testing has certain limitations which must be considered in clinical decision making.